Search research articles
Contact Us
Filters
Showing results (1-10 of 59) with videos related to
Page
of 6
Sort By:
Applied Health Economics and Health Policy
|
November 27, 2024
Estimating a Drug's Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold
Melanie D Whittington, T Joseph Mattingly
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Paying for CAR-T Therapy Amidst Limited Health System Resources
Jonathan D Campbell, Melanie D Whittington
JAMA Pediatrics
|
March 20, 2018
Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies
Melanie D Whittington, R Brett McQueen, Jonathan D Campbell
Neurology. Clinical Practice
|
May 1, 2018
Achieving high value care for all and the perverse incentives of 340B price agreements
Melanie D Whittington, Jonathan D Campbell, R Brett McQueen
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality
|
January 19, 2019
Recommendations for the Use of Audit and Feedback to De-Implement Low-Value Care
Melanie D Whittington, P Michael Ho, Christian D Helfrich
Pharmacoeconomics
|
July 17, 2023
An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year
Jonathan D Campbell, Melanie D Whittington, Steven D Pearson
Neurology
|
January 13, 2022
Performing Cost-Effectiveness Analyses to Support Policy Making: Key Lessons From the Assessment of Aducanumab
Jonathan D Campbell, Melanie D Whittington, Steven D Pearson
The American Journal of Managed Care
|
July 24, 2025
Challenges with judging and interpreting a drug's launch price
Melanie D Whittington, Louis P Garrison, Jonathan D Campbell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2019
Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications
Melanie D Whittington, R Brett McQueen, Jonathan D Campbell
JAMA Oncology
|
October 17, 2018
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy
Melanie D Whittington, Daniel A Ollendorf, Jonathan D Campbell
Page
of 6
Search research articles
Search
Showing results (1-10 of 59) with videos related to
Sort By:
Page
of 6
Applied Health Economics and Health Policy
|
November 27, 2024
Estimating a Drug's Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold
Melanie D Whittington, T Joseph Mattingly
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Paying for CAR-T Therapy Amidst Limited Health System Resources
Jonathan D Campbell, Melanie D Whittington
JAMA Pediatrics
|
March 20, 2018
Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies
Melanie D Whittington, R Brett McQueen, Jonathan D Campbell
Neurology. Clinical Practice
|
May 1, 2018
Achieving high value care for all and the perverse incentives of 340B price agreements
Melanie D Whittington, Jonathan D Campbell, R Brett McQueen
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality
|
January 19, 2019
Recommendations for the Use of Audit and Feedback to De-Implement Low-Value Care
Melanie D Whittington, P Michael Ho, Christian D Helfrich
Pharmacoeconomics
|
July 17, 2023
An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year
Jonathan D Campbell, Melanie D Whittington, Steven D Pearson
Neurology
|
January 13, 2022
Performing Cost-Effectiveness Analyses to Support Policy Making: Key Lessons From the Assessment of Aducanumab
Jonathan D Campbell, Melanie D Whittington, Steven D Pearson
The American Journal of Managed Care
|
July 24, 2025
Challenges with judging and interpreting a drug's launch price
Melanie D Whittington, Louis P Garrison, Jonathan D Campbell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2019
Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications
Melanie D Whittington, R Brett McQueen, Jonathan D Campbell
JAMA Oncology
|
October 17, 2018
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy
Melanie D Whittington, Daniel A Ollendorf, Jonathan D Campbell
Page
of 6